Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: A tumor-dependent phenomenon
✍ Scribed by Moniquc R. Bernsen; A. Peter M. Heintz; Harrold J. J. Van Barungen; Alike W. Van Der Velden; Hub F. J. Dullens; Willem Den Otter
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- French
- Weight
- 616 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The efficacy with which disseminated SL2 and P815 tumors, in syngeneic DBA/2 mice, can be eradicated with low-dose recombinant interleukin-2 (rlL-2) therapy is about equal. Treatment (i.p.) of DBA/2 mice, injected i.p. with SL2 or P8 I5 cells on day 0, with rlL-2 (Proleukin) on days 10 to 14 results in a cure rate of 50 to 60% in each case. The in vitro sensitivity of SL2 and P8 I 5 cells to cis-diammine-dichloro-platinum [Ill (cisplatin) is also comparable, although P815 appears to be slightly more sensitive. In vivo, however, therapy with cisplatin is far less effective against P815 than against SL2. In the DBAI2-SL2 model, at all doses tested, combination therapy with cisplatin (administered on day 2) and rlL-2 (administered on days 10-14) resulted in anti-tumor efficacy greater than that of either drug separately. In contrast, in the DBA/Z-P8 I 5 model, cisplatin decreased the anti-tumor efficacy of subsequently applied rlL-2 therapy. As the only difference between the 2 tumor models is the tumor itself, the success of combination therapy with cisplatin and rlL-2 was dependent on tumor characteristics. We